載入...
Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial
Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting β(2)-agonist (LABA)), glycopyrronium bromide (GLY, long-acting muscarinic antagonist) and mometasone furoate...
Na minha lista:
| 發表在: | ERJ Open Res |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
European Respiratory Society
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8053816/ https://ncbi.nlm.nih.gov/pubmed/33898609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00425-2020 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|